Skip to main content
SpringerLink
Log in
Book cover

Endocrine Replacement Therapy in Clinical Practice pp 39–61Cite as

Growth Hormone Therapy in Children and Adults

  • Chapter

  • 118 Accesses

Part of the book series: Contemporary Endocrinology ((COE))

Abstract

The first documented therapeutic use of growth hormone occurred in 1958 in an effort to treat a growth-hormone-deficient adolescent (1). Further studies confirmed that human growth hormone improved the growth of children with severe growth hormone deficiency (GHD). However, because of the limited supply of pituitary-derived growth hormone (GH), treatment was limited to only a few thousand patients and therapy was often sporadic. The use of the pituitary-derived human GH continued until 1985. At that time, a link between the pituitary-derived hormone and Jakob-Creutzfeldt disease was reported, resulting in the cessation of the therapeutic use of this medication (2,3) in the United States. Fortunately, biosynthetic forms of GH quickly became available. With improved safety and essentially limitless supplies, the therapeutic use of GH has increased dramatically.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Raben M. Treatment of pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 1958; 18: 901–903.

    PubMed  CAS  Google Scholar 

  2. Hintz RL. The prismatic case of Creutzfeldt-Jakob disease associated with pituitary growth hormone treatment. J Clin Endocrinol Metab 1995; 80 (8): 2298–2301.

    PubMed  CAS  Google Scholar 

  3. Fradkin JE, Schonberger LB, Mills JL, Creutzfeldt-Jakob disease in pituitary growth hormone recipients in the United States. JAMA 1991; 265 (7): 880–884.

    Google Scholar 

  4. CDC. Clinical growth charts. Centers for Disease Control, Atlanta, GA, 2001.

    Google Scholar 

  5. Tanner JM, Davies PS. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr 1985; 107 (3): 317–229.

    PubMed  CAS  Google Scholar 

  6. Tanner JM. Auxology. In: Kappy MS, Blizzard RM, Migeon CJ, eds. Wilkins: The Diagnosis and Treatment of Endocrine Disorders in Childhood and Adolescence. Charles C. Thomas Publisher, Illinois, 1994, pp. 137–192.

    Google Scholar 

  7. Fitzhardinge PM, Inwood S. Long-term growth in small-for-date children. Acta Paediatr Scand 1989;349:27–33; discussion 34.

    Google Scholar 

  8. Horvath TL, et al. Minireview: ghrelin and the regulation of energy balance-a hypothalamic perspective. Endocrinology 2001; 142 (10): 4163–4169.

    PubMed  CAS  Google Scholar 

  9. Pombo M, et al. Hormonal control of growth hormone secretion. Horm Res 2001; 55: 11–16.

    PubMed  CAS  Google Scholar 

  10. Van Cauter E, Plat L. Physiology of growth hormone secretion during sleep. J Pediatr 1996; 128 (5 Pt 2): S32–37.

    PubMed  Google Scholar 

  11. Radetti G, Bozzola M, Pagamini C, et al. Growth hormone bioactivity and levels of growth hormone, growth hormone-binding protein, insulinlike growth factor I, and insulinlike growth factor-binding proteins in premature and full-term newborns during the first month of life. Arch Pediatr Adolesc Med 1997; 151 (2): 170–175.

    PubMed  CAS  Google Scholar 

  12. Rose SR, Municchi G, Barnes KM, et al. Spontaneous growth hormone secretion increases during puberty in normal girls and boys. J Clin Endocrinol Metab 1991; 73 (2): 428–435.

    PubMed  CAS  Google Scholar 

  13. Costin G, Kaufman FR. Growth hormone secretory patterns in children with short stature. J Pediatr 1987; 110 (3): 362–368.

    PubMed  CAS  Google Scholar 

  14. van Coevorden A, Mockel J, Laurent E, et al. Neuroendocrine rhythms and sleep in aging men. Am J Physiol 1991; 260 (4 Pt 1): E651–661.

    PubMed  Google Scholar 

  15. Martin-Hernandez T, Galvaz MD, Cuadro AT, et al. Growth hormone secretion in normal prepubertal children: importance of relations between endogenous secretion, pulsatility and body mass. Clin Endocrinol (Oxf) 1996; 44 (3): 327–334.

    CAS  Google Scholar 

  16. Humbel RE. Insulin-like growth factors I and II. Eur J Biochem 1990; 190 (3): 445–462.

    PubMed  CAS  Google Scholar 

  17. Le Roith D, Scavo L, ButlerA. What is the role of circulating IGF-I? Trends Endocrinol Metab 2001; 12 (2): 48–52.

    PubMed  CAS  Google Scholar 

  18. Hesse V, Jahreis G, Schambach H, et al. Insulin-like growth factor I correlations to changes of the hormonal status in puberty and age. Exp Clin Endocrinol 1994; 102 (4): 289–298.

    PubMed  CAS  Google Scholar 

  19. Attie KM, Julius JR, Stoppani C, et al. National Cooperative Growth Study substudy VI: the clinical utility of growth-hormone-binding protein, insulin-like growth factor I, and insulin-like growth factor-binding protein 3 measurements. J Pediatr 1997; 131 (1 Pt 2): S56–60.

    PubMed  CAS  Google Scholar 

  20. Nunez SB, Municchi G, Barnes KM, et al. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 concentrations compared to stimulated and night growth hormone in the evaluation of short children-a clinical research center study. J Clin Endocrinol Metab 1996; 81 (5): 1927–1932.

    PubMed  CAS  Google Scholar 

  21. Neely EK, Rosenfeld RG. Use and abuse of human growth hormone. Annu Rev Med 1994; 45: 407–420.

    PubMed  CAS  Google Scholar 

  22. Frasier SD. A review of growth hormone stimulation tests in children. Pediatrics 1974; 53 (6): 929–937.

    PubMed  CAS  Google Scholar 

  23. Ghigo E, Bellone J, Aimaretti G, et al. Reliability of provocative tests to assess growth hormone secretory status. Study in 472 normally growing children. J Clin Endocrinol Metab 1996; 81 (9): 3323–3327.

    PubMed  CAS  Google Scholar 

  24. Shah A, Stanhope R, Matthew D. Hazards of pharmacological tests of growth hormone secretion in childhood. Br Med J 1992;304(6820):173,174.

    Google Scholar 

  25. Rowe DW, Sare Z, Kelley VC. Possible complications of the levodopa-propranolol test. Pediatrics 1977;60(1): 132,133.

    Google Scholar 

  26. Adan L, Souberbielle JC, Brauner R. Diagnostic markers of permanent idiopathic growth hormone deficiency. J Clin Endocrinol Metab 1994; 78 (2): 353–358.

    PubMed  CAS  Google Scholar 

  27. Carel JC, Tresca JP, Letrait M, et al. Growth hormone testing for the diagnosis of growth hormone deficiency in childhood: a population register-based study. J Clin Endocrinol Metab 1997; 82 (7): 2117–2121.

    PubMed  CAS  Google Scholar 

  28. Tassoni P, Cacciari E, Cau M, et al. Variability of growth hormone response to pharmacological and sleep tests performed twice in short children. J Clin Endocrinol Metab 1990; 71 (1): 230–234.

    PubMed  CAS  Google Scholar 

  29. Rosenfeld RG, Albertsson-Wikand K, Cassorla F, et al. Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab 1995; 80 (5): 1532–1540.

    PubMed  CAS  Google Scholar 

  30. Van den Broeck J, et al. Interpretative difficulties with growth hormone provocative retesting in childhood-onset growth hormone deficiency. Horm Res 1999; 51 (1): 1–9.

    PubMed  Google Scholar 

  31. Maghnie M, et al. Growth hormone (GH) deficiency (GHD) of childhood onset: reassessment of GH status and evaluation of the predictive criteria for permanent GHD in young adults. J Clin Endocrinol Metab 1999; 84 (4): 1324–1328.

    PubMed  CAS  Google Scholar 

  32. Marin G, Domene HM, Barnes KM, The effects of estrogen priming and puberty on the growth hormone response to standardized treadmill exercise and arginine-insulin in normal girls and boys. J Clin Endocrinol Metab 1994; 79 (2): 537–541.

    PubMed  CAS  Google Scholar 

  33. Mauras N, et al, Growth hormone stimulation testing in both short and normal statured children: use of an immunofunctional assay. Pediatr Res, 2000; 48 (5): 614–618.

    PubMed  CAS  Google Scholar 

  34. Guyda HJ. Growth hormone testing and the short child. Pediatr Res 2000;48(5):579,580.

    Google Scholar 

  35. Florini JR, Prinz PN, Vitello MV, et al. Somatomedin-C levels in healthy young and old men: relationship to peak and 24-hour integrated levels of growth hormone. J Gerontol 1985; 40 (1): 2–7.

    PubMed  CAS  Google Scholar 

  36. Veldhuis JD, Iranmanesh A. Physiological regulation of the human growth hormone (GH)-insulinlike growth factor type I (IGF-I) axis: predominant impact of age, obesity, gonadal function, and sleep. Sleep 1996; 19 (Suppl 10): S221–224.

    PubMed  CAS  Google Scholar 

  37. Celniker AC, Chen AB, Wert RM Jr, et al. Variability in the quantitation of circulating growth hormone using commercial immunoassays. J Clin Endocrinol Metab 1989; 68 (2): 469–476.

    PubMed  CAS  Google Scholar 

  38. Granada ML, Sanmarti A, Lucas A, Assay-dependent results of immunoassayable spontaneous 24-hour growth hormone secretion in short children. Acta Paediatr Scand 1990;370:63–70; discussion 71.

    Google Scholar 

  39. Donaldson DL, Hallowell JG, Pan F, et al. Growth hormone secretory profiles: variation on consecutive nights. J Pediatr 1989; 115 (1): 51–56.

    PubMed  CAS  Google Scholar 

  40. Spiliotis BE, August GP, Hung W, Growth hormone neurosecretory dysfunction. A treatable cause of short stature. JAMA 1984; 251 (17): 2223–2230.

    Google Scholar 

  41. Plotnick LP, Lee PA, Migeon CJ, et al. Comparison of physiological and pharmacological tests of growth hormone function in children with short stature. J Clin Endocrinol Metab 1979; 48 (5): 811–815.

    PubMed  CAS  Google Scholar 

  42. Bercu BB, Shulman D, Root AW, et al. Growth hormone (GH) provocative testing frequently does not reflect endogenous GH secretion. J Clin Endocrinol Metab 1986; 63 (3): 709–716.

    PubMed  CAS  Google Scholar 

  43. Rose SR, Ross JL, Uriarte M, et al. The advantage of measuring stimulated as compared with spontaneous growth hormone levels in the diagnosis of growth hormone deficiency. N Engl J Med 1988; 319 (4): 201–207.

    PubMed  CAS  Google Scholar 

  44. Rosenfeld RG, Wilson DM, Lee PK, et al. Insulin-like growth factors I and II in evaluation of growth retardation. J Pediatr 1986; 109 (3): 428–433.

    PubMed  CAS  Google Scholar 

  45. Rosenfeld RG. Is growth hormone deficiency a viable diagnosis? J Clin Endocrinol Metab 1997; 82 (2): 349–351.

    PubMed  CAS  Google Scholar 

  46. Hoffman DM, O’Sullivan AJ, Baxter RC, et al. Diagnosis of growth-hormone deficiency in adults. Lancet 1994; 343 (8905): 1064–1068.

    PubMed  CAS  Google Scholar 

  47. Ghigo E, et al. Diagnosis of GH deficiency in adults. Growth Horm IGF Res 1998; 8: 55–58.

    PubMed  Google Scholar 

  48. Baum HB, Biller BMK, Katznelson L, et al. Assessment of growth hormone (GH) secretion in men with adult-onset GH deficiency compared with that in normal men-a clinical research center study. J Clin Endocrinol Metab 1996; 81 (1): 84–92.

    PubMed  CAS  Google Scholar 

  49. Attanasio AF, Lamberts SWJ, Matranga AMC, et al. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. J Clin Endocrinol Metab 1997; 82 (1): 82–88.

    PubMed  CAS  Google Scholar 

  50. Werther GA. Growth hormone measurements versus auxology in treatment decisions: the Australian experience. J Pediatr 1996; 128 (5 Pt 2): S47–51.

    PubMed  CAS  Google Scholar 

  51. Wilson DM. Clinical actions of growth hormone. Endocrinol Metab Clin N Am 1992; 21 (3): 519–537.

    CAS  Google Scholar 

  52. Ruokonen E, Takala J. Dangers of growth hormone therapy in critically ill patients. Ann Med 2000; 32 (5): 317–322.

    PubMed  CAS  Google Scholar 

  53. Takala J, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 341 (11): 785–792.

    PubMed  CAS  Google Scholar 

  54. Fidotti E. A history of growth hormone injection devices. J Pediatr Endocrinol Metab 2001; 14 (5): 497–501.

    PubMed  CAS  Google Scholar 

  55. Reiter EO, et al. A multicenter study of the efficacy and safety of sustained release GH in the treatment of naive pediatric patients with GH deficiency. J Clin Endocrinol Metab 2001; 86 (10): 4700–4706.

    PubMed  CAS  Google Scholar 

  56. MacGillivray MH, Baptista J, Johanson A. Outcome of a four-year randomized study of daily versus three times weekly somatropin treatment in prepubertal naive growth hormone-deficient children. Genentech Study Group. J Clin Endocrinol Metab 1996; 81 (5): 1806–1809.

    PubMed  CAS  Google Scholar 

  57. Mauras N, et al. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group. J Clin Endocrinol Metab 2000; 85 (10): 3653–3660.

    PubMed  CAS  Google Scholar 

  58. Drake WM, et al. Optimizing gh therapy in adults and children. Endocr Rev 2001; 22 (4): 425–450.

    PubMed  CAS  Google Scholar 

  59. de Boer H, Blok GJ, Popp-Snijders C, et al. Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers. J Clin Endocrinol Metab 1996; 81 (4): 1371–1377.

    PubMed  Google Scholar 

  60. Johansson AG. Gender difference in growth hormone response in adults. J Endocrinol Invest 1999; 22 (Suppl 5): 58–60.

    PubMed  CAS  Google Scholar 

  61. Span JP, et al. Gender differences in rhGH-induced changes in body composition in GH-deficient adults. J Clin Endocrinol Metab 2001; 86 (9): 4161–4165.

    PubMed  CAS  Google Scholar 

  62. Hayes FJ, Fiad TM, McKenna TJ. Gender difference in the response of growth hormone (GH)-deficient adults to GH therapy. Metabolism 1999; 48 (3): 308–313.

    PubMed  CAS  Google Scholar 

  63. Maneatis T, et al. Growth hormone safety update from the National Cooperative Growth Study. J Pediatr Endocrinol Metab 2000; 13 (Suppl 2): 1035–1044.

    PubMed  Google Scholar 

  64. Massa G, Vanderschueren-Lodeweyckx M, Bouillon R. Five-year follow-up of growth hormone antibodies in growth hormone deficient children treated with recombinant human growth hormone. Clin Endocrinol (Oxf) 1993; 38 (2): 137–142.

    CAS  Google Scholar 

  65. Kaplan SL, August GP, Blethen SL, et al. Clinical studies with recombinant-DNA-derived methionyl human growth hormone in growth hormone deficient children. Lancet 1986; 1 (8483): 697–700.

    PubMed  CAS  Google Scholar 

  66. Milner RD, Barnes ND, Buckler JMH, et al. United Kingdom multicentre clinical trial of somatrem. Arch Dis Child 1987; 62 (8): 776–779.

    PubMed  CAS  Google Scholar 

  67. Pirazzoli P, Cacciari E, Mandini M, et al. Follow-up of antibodies to growth hormone in 210 growth hormone-deficient children treated with different commercial preparations. Acta Paediatr 1995; 84 (11): 1233–1236.

    PubMed  CAS  Google Scholar 

  68. Malozowski S, Tanner LA, Wysowski D, Growth hormone, insulin-like growth factor I, and benign intracranial hypertension. N Engl J Med 1993;329(9):665,666.

    Google Scholar 

  69. Allen DB. Safety of human growth hormone therapy: current topics. J Pediatr 1996; 128 (5 Pt 2): S8–13.

    PubMed  CAS  Google Scholar 

  70. Malozowski S, Stadel BV. Prepubertal gynecomastia during growth hormone therapy. J Pediatr 1995; 126 (4): 659–661.

    PubMed  CAS  Google Scholar 

  71. Bertelloni S, et al. Can growth hormone treatment in boys without growth hormone deficiency impair testicular function? J Pediatr 1999; 135 (3): 367–370.

    PubMed  CAS  Google Scholar 

  72. Leschek EW, et al. Effect of growth hormone treatment on testicular function, puberty, and adrenarche in boys with non-growth hormone-deficient short stature: a randomized, double-blind, placebo-controlled trial. J Pediatr 2001; 138 (3): 406–410.

    PubMed  CAS  Google Scholar 

  73. Wantanabee S, Tsunematsu Y, Fujimoto J, Leukaemia in patients treated with growth hormone. Lancet 1988;1(8595): 1159, 1160.

    Google Scholar 

  74. Allen DB, et al. Risk of leukemia in children treated with human growth hormone: review and reanalysis. J Pediatr 1997; 131 (1 Pt 2): S32–36.

    PubMed  CAS  Google Scholar 

  75. Shalet SM, Brennan BM, Reddingius RE. Growth hormone therapy and malignancy. Horm Res 1997; 48 (Suppl 4): 29–32.

    PubMed  CAS  Google Scholar 

  76. Cohen P, Clemmons DR, Rosenfeld RG. Does the GH-IGF axis play a role in cancer pathogenesis? Growth Horm IGF Res 2000; 10 (6): 297–305.

    PubMed  CAS  Google Scholar 

  77. Beshyah SA, Freemantle C, Shah M, et al. Replacement treatment with biosynthetic human growth hormone in growth hormone-deficient hypopituitary adults. Clin Endocrinol (Oxf) 1995; 42 (1): 73–84.

    CAS  Google Scholar 

  78. Baum HB, Biller BMK, Finklestein S, et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 1996; 125 (11): 883–890.

    PubMed  CAS  Google Scholar 

  79. Procter AM, Phillips JA 3rd, Cooper DA. The molecular genetics of growth hormone deficiency. Hum Genet 1998; 103 (3): 255–272.

    PubMed  CAS  Google Scholar 

  80. Lindsay R, et al. Utah Growth Study: growth standards and the prevalence of growth hormone deficiency. J Pediatr 1994; 125 (1): 29–35.

    PubMed  CAS  Google Scholar 

  81. Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Guidelines for the use of growth hormone in children with short stature. J Pediatr 1995; 127 (6): 857–867.

    Google Scholar 

  82. Coste J, Letrait M, Carel JC, et al. Long-term results of growth hormone treatment in France in children of short stature: population, register based study. Br Med J 1997; 315 (7110): 708–713.

    CAS  Google Scholar 

  83. Coutant R, et al. Growth and adult height in GH-treated children with nonacquired GH deficiency and idiopathic short stature: the influence of pituitary magnetic resonance imaging findings. J Clin Endocrinol Metab 2001; 86 (10): 4649–4654.

    PubMed  CAS  Google Scholar 

  84. Bengtsson BA, et al. Treatment of growth hormone deficiency in adults. J Clin Endocrinol Metab 2000; 85 (3): 933–942.

    PubMed  CAS  Google Scholar 

  85. Barkan AL, et al. Growth hormone therapy for hypopituitary adults: time for re-appraisal. Trends Endocrinol Metab 2000; 11 (6): 238–245.

    PubMed  CAS  Google Scholar 

  86. Carroll PV, Christ ER, Sonksen PH. Growth hormone replacement in adults with growth hormone deficiency: assessment of current knowledge. Trends Endocrinol Metab 2000; 11 (6): 231–238.

    PubMed  CAS  Google Scholar 

  87. Nicolson A, et al. The prevalence of severe growth hormone deficiency in adults who received growth hormone replacement in childhood (see comment). Clin Endocrinol (Oxf) 1996; 44 (3): 311–316.

    CAS  Google Scholar 

  88. Nass R, Huber RM, Klauss V, et al. Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency acquired in adulthood. J Clin Endocrinol Metab 1995; 80 (2): 552–557.

    PubMed  CAS  Google Scholar 

  89. Allen DB, Brook CGD, Bridges NA, et al. Therapeutic controversies: growth hormone (GH) treatment of non-GH deficient subjects. J Clin Endocrinol Metab 1994; 79 (5): 1239–1248.

    PubMed  CAS  Google Scholar 

  90. Loche S, Cambiaso P, Setzu S, et al. Final height after growth hormone therapy in non-growthhormone-deficient children with short stature. J Pediatr 1994; 125 (2): 196–200.

    PubMed  CAS  Google Scholar 

  91. Guyda HJ. Four decades of growth hormone therapy for short children: what have we achieved? J Clin Endocrinol Metab 1999; 84 (12): 4307–4316.

    PubMed  CAS  Google Scholar 

  92. Wit JM, Massarano AA, Kamp GA, et al. Growth hormone secretion in patients with Turner’s syndrome as determined by time series analysis. Acta Endocrinol (Copenh) 1992; 127 (1): 7–12.

    CAS  Google Scholar 

  93. Ranke MB, Blum WF, Haug F, et al. Growth hormone, somatomedin levels and growth regulation in Turner’ s syndrome. Acta Endocrinol (Copenh) 1987; 116 (3): 305–313.

    CAS  Google Scholar 

  94. Schmitt K, Haeusler G, Blumel P, et al. Short-and long-term (final height) growth responses to growth hormone (GH) therapy in patients with Turner syndrome: correlation of growth response to stimulated GH levels, spontaneous GH secretion, and karyotype. Horm Res 1997; 47 (2): 67–72.

    PubMed  CAS  Google Scholar 

  95. Pasquino AM, Passeri F, Municchi G, et al. Final height in Turner syndrome patients treated with growth hormone. Horm Res 1996; 46 (6): 269–272.

    PubMed  CAS  Google Scholar 

  96. Takano K, Ogawa M, Tanaka T, et al. Clinical trials of GH treatment in patients with Turner’ s syndrome in Japan-a consideration of final height. The Committee for the Treatment of Turner’ s Syndrome. Eur J Endocrinol 1997; 137 (2): 138–145.

    PubMed  CAS  Google Scholar 

  97. Rosenfeld RG, et al. Growth hormone therapy of Turner’s syndrome: beneficial effect on adult height. J Pediatr 1998; 132 (2): 319–324.

    PubMed  CAS  Google Scholar 

  98. Kohaut EC, Fine RN. Testing for growth hormone release is not necessary prior to treatment of children with chronic renal insufficiency with recombinant human growth hormone. Kidney Int 1996; 53: 5119–122.

    Google Scholar 

  99. Fine RN, et al. The impact of recombinant human growth hormone treatment during chronic renal insufficiency on renal transplant recipients. J Pediatr 2000; 136 (3): 376–382.

    PubMed  CAS  Google Scholar 

  100. Fine RN, Kohaut E, Brown D, et al. Long-term treatment of growth retarded children with chronic renal insufficiency, with recombinant human growth hormone. Kidney Int 1996; 49 (3): 781–785.

    PubMed  CAS  Google Scholar 

  101. Haffner D, Schaefer F. Does recombinant growth hormone improve adult height in children with chronic renal failure? Semin Nephro1, 2001; 21 (5): 490–497.

    CAS  Google Scholar 

  102. Mentser M, Breen TJ, Sullivan D, et al. Growth-hormone treatment of renal transplant recipients: the National Cooperative Growth Study experience-a report of the National Cooperative Growth Study and the North American Pediatric Renal Transplant Cooperative Study. J Pediatr 1997; 131 (1 Pt 2): S20–24.

    PubMed  CAS  Google Scholar 

  103. Luo ZC, Albertsson-Wikland K, Karlberg J. Length and body mass index at birth and target height influences on patterns of postnatal growth in children born small for gestational age. Pediatrics 1998; 102 (6): E72.

    PubMed  CAS  Google Scholar 

  104. Sas T, et al. Growth hormone treatment in children with short stature born small for gestational age: 5-year results of a randomized, double-blind, dose-response trial. J Clin Endocrinol Metab 1999; 84 (9): 3064–3070.

    PubMed  CAS  Google Scholar 

  105. de Zegher F, et al. Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: results over 6 years. J Clin Endocrinol Metab 1999; 84 (5): 1558–1561.

    PubMed  Google Scholar 

  106. de Zegher F, et al. Growth hormone treatment of short children born small for gestational age: growth responses with continuous and discontinuous regimens over 6 years. J Clin Endocrinol Metab 2000; 85 (8): 2816–2821.

    PubMed  Google Scholar 

  107. Lee PD, et al. Linear growth response to exogenous growth hormone in Prader-Willi syndrome. Am J Med Genet 1987; 28 (4): 865–871.

    PubMed  CAS  Google Scholar 

  108. Lindgren AC, et al. Effects of growth hormone treatment on growth and body composition in PraderWilli syndrome: a preliminary report. The Swedish National Growth Hormone Advisory Group. Acta Paediatr Suppl, 1997; 423: 60–62.

    PubMed  CAS  Google Scholar 

  109. Carrel AL, et al. Sustained benefits of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome are dose-dependent. J Pediatr Endocrinol Metab 2001; 14 (8): 1097–1105.

    PubMed  CAS  Google Scholar 

  110. Myers SE, et al. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome. J Pediatr 2000; 137 (1): 42–49.

    PubMed  CAS  Google Scholar 

  111. Eiholzer U, et al. Body composition abnormalities in children with Prader-Willi syndrome and longterm effects of growth hormone therapy. Horm Res 2000; 53 (4): 200–206.

    PubMed  CAS  Google Scholar 

  112. Lee PD. Effects of growth hormone treatment in children with Prader-Willi syndrome. Growth Horm IGF Res 2000; 10 (Suppl B): S75–79.

    PubMed  Google Scholar 

  113. Zipf WB. Glucose homeostasis in Prader-Willi syndrome and potential implications of growth hormone therapy. Acta Paediatr 1999; 88 (433): 115–117.

    CAS  Google Scholar 

  114. Lee P, et al. Consensus statement Prader-Willi syndrome: growth hormone (GH)/insulin-like growth factor axis deficiency and GH treatment. Endocrinol 2000; 10: S71–73.

    Google Scholar 

Download references

Authors
  1. Darrell M. Wilson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Endocrinology, Diabetes and Metabolism, Department of Medicine and Pathology, University of Utah School of Medicine and ARUP Laboratory, Salt Lake City, UT, USA

    A. Wayne Meikle MD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Wilson, D.M. (2003). Growth Hormone Therapy in Children and Adults. In: Meikle, A.W. (eds) Endocrine Replacement Therapy in Clinical Practice. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-375-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-375-0_3

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-416-6

  • Online ISBN: 978-1-59259-375-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation